Biotechnology company Complement Therapeutics has appointed a new member to its board to help support the company with its development goals.
Complement Therapeutics appointed Steve Axon as in independent director to its Board of Directors who will help the company with its goals of addressing unmet needs in complement mediated diseases such as geographic atrophy due to dry age-related macular degeneration, a major cause of vision loss and blindness.
Axon has over 20 years of experience in the industry and is currently the CEO of Glycomine, a clinical-stage company focused on developing new therapies for serious unserved orphan diseases. He previously served as CEO of Prothelia, a preclinical company focused on muscular dystrophy, as Chief Business Officer at Apellis, and as Senior Vice President of Business Development at Merck KGaA.
Dr Rafiq Hasan, CEO, Complement Therapeutics commented: “It is a real pleasure and privilege to welcome Steve to our Board. His expertise and experience in both complement mediated conditions and the sector more broadly will be invaluable to the company as we drive forward our novel pipeline and analytics platform.”
Steve Axon, independent director, added: “I am excited to be joining the Board of CTx at such an exciting time and look forward to working with the growing team to develop innovative medicines addressing significant unmet need in both ophthalmology and broader complement driven diseases.”